* New formulation of Acetadote to replace current product
* Co to immediately start U.S. launch activities
* Shares rise 19 pct after the bell
Jan 13 (Reuters) - Cumberland Pharmaceuticals Inc said U.S. health regulators approved a new formulation of its drug for treating acetaminophen poisoning and it would replace the currently marketed product.
The company, which will stop manufacturing the older formulation, said it will immediately commence U.S. launch activities for the next generation Acetadote injection.
Acetadote has been available in the United States since 2004 and is currently used in hospital emergency departments to prevent or lessen potential liver damage resulting from an overdose of acetaminophen.
Acetaminophen is a common ingredient in many over-the-counter pain relief and fever-reducing drugs.
Cumberland also obtained approval for an extended shelf life of 30 months with the new product, up from the 24 months for the original formulation.
The company's shares rose 19 percent to $6.73 in after-hours trade on Thursday. They have lost 7 percent since it voluntarily recalled 6 lots of Acetadote in December due to presence of fine particles in some vials.
(Reporting by Esha Dey in Bangalore; Editing by Gopakumar Warrier) Keywords: CUMBERLAND/ (esha.dey@thomsonreuters.com; within U.S. +1 646 223 8780; outside U.S. +91 80 4135 5800; Reuters Messaging: esha.dey.thomsonreuters.com@reuters.net) COPYRIGHT Copyright Thomson Reuters 2011. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
* Co to immediately start U.S. launch activities
* Shares rise 19 pct after the bell
Jan 13 (Reuters) - Cumberland Pharmaceuticals Inc said U.S. health regulators approved a new formulation of its drug for treating acetaminophen poisoning and it would replace the currently marketed product.
The company, which will stop manufacturing the older formulation, said it will immediately commence U.S. launch activities for the next generation Acetadote injection.
Acetadote has been available in the United States since 2004 and is currently used in hospital emergency departments to prevent or lessen potential liver damage resulting from an overdose of acetaminophen.
Acetaminophen is a common ingredient in many over-the-counter pain relief and fever-reducing drugs.
Cumberland also obtained approval for an extended shelf life of 30 months with the new product, up from the 24 months for the original formulation.
The company's shares rose 19 percent to $6.73 in after-hours trade on Thursday. They have lost 7 percent since it voluntarily recalled 6 lots of Acetadote in December due to presence of fine particles in some vials.
(Reporting by Esha Dey in Bangalore; Editing by Gopakumar Warrier) Keywords: CUMBERLAND/ (esha.dey@thomsonreuters.com; within U.S. +1 646 223 8780; outside U.S. +91 80 4135 5800; Reuters Messaging: esha.dey.thomsonreuters.com@reuters.net) COPYRIGHT Copyright Thomson Reuters 2011. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.